MinireviewUbiquitin-dependent proteolysis: its role in human diseases and the design of therapeutic strategies
Introduction
Ubiquitin (Ub)-dependent proteolysis of key regulatory proteins impacts various cellular processes such as cell cycle progression, transcription, antigen presentation, receptor endocytosis, fate determination, and signal transduction [1], [2]. With so many cellular pathways affected, it is therefore not surprising that derangements in the Ub-proteolytic pathway contribute to the etiology of several diseases. In this review, we will summarize our current understanding of how Ub-dependent degradation takes place in the cell and the various steps at which an impairment of the normal pathway contributes to the diseased state. We will conclude by summarizing the different ways we, as well as others, are utilizing the cellular degradation machinery to develop therapeutic strategies to treat human diseases.
Section snippets
The Ubiquitin system
Ubiquitin is one of the most conserved proteins in eukaryotes. It is a small 76-amino acid protein that is conjugated to other proteins through an energy-dependent enzymatic pathway [1], [3]. Conjugation is initiated by the activation of Ub by the Ub-activating enzyme, E1, which forms a high-energy Ub-thiol ester bond in the presence of ATP (Fig. 1). It then transfers the activated Ub to a Ub-conjugating enzyme, E2, forming an E2-thiol ester bond. Finally, ubiquitin is transferred to a target
Cervical cancer
Among the best-characterized associations between cancer and the ubiquitin ligase pathway is that of cancer of the uterine cervix. This is the third most common cancer diagnosed in women. While the precise cause of cervical cancer remains uncertain, the disease is strongly associated with infections by the oncogenic forms of HPV, types 16 and 18. The E6 and E7 proteins of these high risk strains are often detected in cervical cancers [44]. In these same carcinomas, the levels of tumor
Potential therapeutic strategies
Given the fact that all mammalian cells have ubiquitin ligases and proteasomes, selectively targeting proteins for ubiquitination and degradation is a potential avenue for drug development. Moreover, since there is recent information about the crystal structure of ubiquitin ligases and their substrates, one could imagine using low molecular weight compounds to stabilize or degrade proteins to treat a variety of diseases. Several approaches have been considered, including gene therapy to
Acknowledgements
I thank Ray Deshaies for his support and helpful comments, Rati Verma for helpful suggestions and critical reading of the manuscript, Craig Crews for providing the Protacs, and Ning Zheng for providing purified Cbl, ubch4, and GST-E1 for ubiquitination assays. This work was supported by CaPCURE and the UC BioSTAR Project (biostar 01-10232). I also thank Frank Mercurio and Celgene, Signal Research Division for supporting this work and providing reagents. K.M.S. is a Scholar of the Leukemia and
References (107)
- et al.
A proteasome howdunit: the case of the missing signal
Cell
(2000) - et al.
The lore of the RINGs: Substrate recognition and catalysis by ubiquitin ligases
Trends Cell Biol.
(2000) - et al.
The PHD domain of MEKK1 acts as an E3 ubiquitin ligase and mediates ubiquitination and degradation of ERK1/2
Mol. Cell
(2002) - et al.
The U box is a modified RING finger—a common domain in ubiquitination
Curr. Biol.
(2000) - et al.
The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53
Cell
(1993) - et al.
Does this have a familiar RING?
Trends Biochem. Sci.
(1996) - et al.
F-box proteins are receptors that recruit phosphorylated substrates to the SCF ubiquitin-ligase complex
Cell
(1997) - et al.
A complex of Cdc4p, Skp1p, and Cdc53p/cullin catalyzes ubiquitination of the phosphorylated CDK inhibitor Sic1p
Cell
(1997) - et al.
Functional analysis of FAR1 in yeast
Methods Enzymol.
(1997) - et al.
Cullin 4A associates with the UV-damaged DNA-binding protein DDB
J. Biol. Chem.
(1999)